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Our bodies are colonized by a complex ecosystem of bacteria, unicellular
eukaryotes and their viruses that together play a major role in our health.
Over the past few years tools derived from the prokaryotic immune
system known as CRISPR-Cas have empowered researchers to modify and
study organisms with unprecedented ease and efficiency. Here we discuss
how various types of CRISPR-Cas systems can be used to modify the
genome of gut microorganisms and bacteriophages. CRISPR-Cas systems
can also be delivered to bacterial population and programmed to specifically
eliminate members of the microbiome. Finally, engineered CRISPR-Cas
systems can be used to control gene expression and modulate the production
of metabolites and proteins. Together these tools provide exciting opport-
unities to investigate the complex interplay between members of the
microbiome and our bodies, and present new avenues for the development
of drugs that target the microbiome.
This article is part of a discussion meeting issue ‘The ecology and
evolution of prokaryotic CRISPR-Cas adaptive immune systems’.1. Introduction
Healthy humans live in a symbiotic relationship with trillions of microorganisms
that inhabit the exposed surfaces of our bodies and play an essential role in the
maturation of the host-immune response, production of metabolites, brain–gut
axis and more (see reviews [1–4]). This close relationship makes our microbiome
an interesting target for therapies with the goal to induce desired responses,
immunological, metabolic or even neurological in nature. These therapies can be
classified into three main types: (i) additive therapies supplementing the host
microbiota with individual strains or consortiums of bacterial species, (ii) subtrac-
tive therapies aiming to eliminate disease-causingmembers of themicrobiome, and
(iii) modulatory therapies aiming to modulate the composition or activity of the
endogenous microbiome (see reviews [5,6]). While these therapeutic approaches
are still in their infancy, engineered bacteria and viruses can be used to achieve
desired outcomes [6]. In this review, we describe how tools derived from the pro-
karyotic immune system known as clustered regularly interspaced short
palindromic repeats (CRISPRs)—and CRISPR-associated (Cas) proteins can be
used to modify or eliminate members of the microbiome (figure 1).
CRISPR-Cas systems are the adaptive immune system of bacteria and archaea
[7]. The strong interest in these systems comes from the discoveryof a set of diverse
RNA-guided nucleases able to destroy target nucleic acid sequences, some DNA
and other RNA. The Cas nucleases are guided by CRISPR RNAs (crRNA), pro-
duced by transcription and processing of the CRISPR locus: a chromosomal site
into which DNA fragments from invading nucleic acids are integrated in between
repeats, providing amemory of past infections. Cas proteins associated to CRISPR
arrays are very diverse and form the basis of the classification of CRISPR-Cas sys-
tems into two classes and six main types [8,9]. Class 1 systems (types I, III and IV)
consists of a complexmachinery,with severalCasproteins assisting the recognition
of foreign nucleic acids and their cleavage. Class 2 systems (types II, V andVI) have
a simpler protein architecture with a single effector protein arbitrating both recog-
nition and cleavage. The latter class includes the type II CRISPR-Cas9 system,
whose versatility has pushed the limits of genome editing [10]. Some features
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Figure 1. CRISPR approaches to microbiome therapies. CRISPR-Cas systems can be used to engineer designer probiotic strains of bacteria and yeast (additive
therapies). CRISPR-Cas systems can also be used to eliminate target bacteria (subtractive therapies), either through the engineering of designer lytic bacteriophages,
or through the delivery of CRISPR-Cas systems themselves as antimicrobials. Dead Cas proteins can be used to modify gene expression, and engineered temperate
phages can modulate the composition and activity of bacteria in the microbiome (modulatory therapies).
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2unique to type II systems are the double-stranded (ds) DNA
endonuclease Cas9 and the auxiliary trans-acting crRNA
(tracrRNA) [11]. The crRNA and tracrRNA can be fused into a
chimeric single guide RNA (sgRNA) further simplifying the
use of this system as a tool. More recently, Cas nucleases from
other subtypes have been successfully used in a variety of bio-
technological applications. These include the Cas12 (Cpf1)
DNA endonuclease from type V systems as well as the Cas13
nuclease from type VI systems, which targets RNA rather than
DNA [12,13].
CRISPR-Cas systems are present in approximately 40% of
bacteria. Endogenous CRISPR-Cas systems can in some cases
be exploited, and engineered CRISPR-Cas systems can other-
wise be introduced into target bacteria. These systems can be
used to modify the genomes of microbiome-associated or
probiotic bacteria, yeast and bacteriophages. They can also
be used to kill specific strains based on their sequence with-
out touching the rest of the microbiome (figure 1). Finally,
CRISPR-Cas systems can be used to control gene expres-
sion without the need to modify the genome. Altogether
CRISPR-Cas systems offer a powerful set of tools that
will benefit the study of the microbiome and lead to the
development of new strategies to modify it (figure 2).2. CRISPR editing of bacteria
Shortly after its discovery and biochemical characterization,
the CRISPR-Cas9 system was repurposed to edit eukaryoticand bacterial genomes [14]. It can now be considered as a
tool of choice to engineer probiotic strains for additive thera-
pies. Genome editing strategies rely on the use of a guide
RNA designed to target a chromosomal sequence of interest
where Cas9 will cut. Early bioinformatics studies revealed
that bacterial genomes sometimes naturally carry CRISPR-
Cas systems that contain guides targeting their own
chromosome [15]. In most of these cases clues can be ident-
ified showing that the CRISPR-Cas system is inactivated by
mutations in the cas genes or CRISPR array, or mutations
altering the targeted sequences. A model was thus proposed
where the CRISPR-Cas systems sometimes capture self-
targeting spacers ‘by mistake’ and can only survive such
events if the system is functionally inactivated. The idea
that self-targeting of the bacterial chromosome by the
CRISPR-Cas system is lethal was also corroborated by reports
that bacteria die when endogenous or exogenous CRISPR-
Cas systems are programmed to target the chromosome
[16–19]. While the primary outcome of self-targeting is cell
death, some cells are able to survive through the deletion of
large DNA fragments encompassing the target position
[18,20–23]. This strategy offers little to no control over the
extent of DNA that will be deleted, but could still prove
useful in removing undesired genetic elements such as patho-
genicity islands or prophages from strains of interest. Lethal
self-targeting can also be used to counter-select specific
genotypes in complex populations [19,24].
The first evidence that CRISPR-Cas9 could be employed to
achieve precise scar-less genome editing in bacteria came from
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Figure 2. Killing, genome editing or modulation of gene expression by CRISPR-Cas systems. CRISPR-Cas systems can be delivered to target bacteria either in vitro or
in vivo through transformation, transduction or conjugation. Cas nucleases induce DNA breaks that can either lead to DNA degradation and cell death, or if the break
is repaired to the introduction of mutations. Catalytically dead Cas proteins such as dCas9 can be used to silence genes by blocking the RNA polymerase (RNAP).
Dead Cas proteins can also be fused to various protein domains such as activators to induce the expression of genes, or to domains able to modify DNA bases.
royalsocietypublishing.org/journal/rstb
Phil.Trans.R.Soc.B
374:20180103
3a study in which the Cas9 protein from Streptococcus pyogenes
was integrated in the chromosome of Streptococcus pneumoniae,
an opportunistic pathogen commonly present in the respiratory
tract, sinuses and nasal cavities of healthy carriers [25,26].
In this work, the CRISPR-Cas9 system was programmed
to target an antibiotic resistance cassette present in another
strain. When the DNA from the first strain was used to transfer
the CRISPR-Cas9 system to the second strain through natural
transformation, most bacteria died from the activity of the
CRISPR-Cas9 system. Nonetheless, a substantial fraction of
bacteria survived CRISPR-Cas9 killing through the modifi-
cation of the targeted position by homologous recombination
with the locus present in the donor DNA, which did not carry
the antibiotic resistance cassette [26]. This work showed that
Cas9 can be used to select for the introduction of mutations
at desired positions without the need to leave a selection
marker or a scar at the edited position.
While this strategy was easily employed in S. pneumoniae
where natural transformation and recombination are efficient,
its application to less recombinogenic bacteria such as E. coli
requires the use of the phage lambda red recombination
system to promote editing and repair of the Cas9-mediated
breaks [26]. Many studies have now expanded on this work,
making CRISPR-Cas9 editing tools more convenient to use
[27–30]. CRISPR-Cas9 editing strategies typically rely on the
expression of guide RNAs, Cas9 and the lambda red genes
from one or several plasmids. Template DNA can be provided
as short single stranded DNA, short or long double stranded
DNA (typically PCR products), or cloned on a plasmid. In
all cases Cas9 is guided to introduce a break at a position of
interest, which leads to cell death unless the target DNA was
modified, or unless it can be repaired by recombination withthe template DNA. In a different strategy inspired by previous
work with the I-SceI nuclease [31], a non-replicative vector
can be integrated through homologous recombination into
the locus of interest, followed by Cas9 cleavage of the vector
backbone leading to recombination and recovery of the
desired scar-less mutation [32,33]. In all the strategies
above, steps of plasmid curing can also be necessary and are
typically achieved by using the temperature sensitive
pSC101 origin of replication [34]. When more than one plas-
mid is required this can be coupled with other strategies
such as targeting the second plasmid with a guide RNA or
the use of counter-selection markers such as sacB [27–29].
The fairly large number of components involved, and the
necessity to clone a guide RNA as well as in some cases a tem-
plate DNA, can make these strategies more cumbersome than
established methods [35]. CRISPR-Cas9 strategies have none-
theless enabled pushing at the limits of what is possible, in
particular where scar-less mutations are needed [27]. Of par-
ticular interest, a strategy has been devised to perform high-
throughput modifications of many positions in parallel [36].
Pools of oligonucleotides designed to carry both a homolo-
gous repair cassette and a sgRNA can be cloned on a
vector, yielding a library that can be used to perform multi-
plexed recombineering. Another clever strategy enabled the
replacement of large fragments of the E. coli genomewith syn-
thetic DNA [37]. In this study, multiple guide RNAs were used
simultaneously in the same E. coli cell to cleave two positions in
the E. coli chromosome and two positions on a plasmid carry-
ing a synthetic DNA fragment, triggering the replacement of
the chromosomal DNA through homologous recombination.
A novel and powerful approach in the field of genome
editing is the use of the catalytic dead variant of Cas9
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4(dCas9) fused to a cytosine deaminase or an adenosine dea-
minases in order to convert C†G to T†A or A†T to G†C at
specific target positions without the need to introduce a
DNA break [38–40]. In this strategy, cytosines or adenosines
located within a small window 15–25 bp from the proto-
spacer adjacent motif (PAM) are modified, leading to a
somewhat random mutational outcome when several C or
A are present in the target window. Nonetheless this
approach appears to be very efficient and can easily be
used to modify many positions in parallel. In a recent study,
Kondo and colleagues optimized this strategy for E. coli and
were able to modify up to 41 loci simultaneously [41].
CRISPR-Cas9 genome editing tools are already being
employed to investigate basic biological questions, as well
as in applications such as metabolic engineering [42]. While
these applications are not directly related to microbiome
engineering, we should keep in mind that E. coli is a gut bac-
terium that can be used as a probiotic. Probiotic E. coli strains,
like Nissle 1917, have been engineered to express antigens
[43], antimicrobial compounds [44], enzymes to disperse bio-
films, quorum sensing molecules that control pathogen
virulence [45], metabolic functions of interest and more [6].
These current efforts to engineer probiotic E. coli strains will
certainly benefit from this boon of new tools.
Beyond E. coli, the most commonly used probiotic bacteria
are Bifidobacteria and Lactobacilli. Engineered Lactobacilli are
being developed by various biotech companies as targeted
therapies against a wide range of diseases including oral
mucositis, inflammatory bowel disease, viral and bacterial
infections [46]. The ability of Bifidobacterium to proliferate in
solid tumours offers the possibility to engineer them to pro-
duce cancer-suppressing compounds [47]. While CRISPR
tools for Bifidobacteria have yet to be developed, Oh and
van Pijkeren developed a method to perform genome editing
in Lactobacillus reuteri ATCC PTA 6475 [48], a bacteria shown
to have interesting immunomodulatory and antimicrobial
properties [49,50]. Modifications can be introduced by recom-
bination of a single stranded DNA oligonucleotide mediated
by the RecT protein, followed by selection with Cas9.
CRISPR-Cas9 mediated genome editing was also recently
demonstrated in Lactobacillus plantarum, where putting the
recombination template on a plasmid rather than providing
it as single stranded DNA led to the best results [51]. Barran-
gou and colleagues have recently highlighted how CRISPR
tools could be used to enhance therapeutic effects of lactic
acid bacteria [52]. For instance, researchers are exploring strat-
egies to enhance bile salt hydrolase activity to improve strain
survival in the gut, or to modify surface layer-associated
proteins to change their immunomodulatory properties.
Other bacteria of interest include the Clostridia, a diverse
class of bacteria that include strains of industrial interest but
also many commensals of the gut microbiome, of which a
few—and most notoriously Clostridium difficile—can be
opportunistic pathogens. Several reports have demonstrated
the use of CRISPR tools to modify species of biotechnological
interest including Clostridium acetobutylicum, Clostridium bei-
jerinckii and Clostridium cellulolyticum [53–55]. CRISPR-Cas9
tools have now also enabled the engineering of C. difficile
[56,57]. Note that non-toxigenic Clostridia, including non-
toxigenic C. difficile, form part of the normal human gut
microbiome [58] and could potentially be engineered as inter-
esting probiotics. Clostridium butyricum MIYAIRI 588 has
notably been developed as a probiotic against C. difficileinfections [59], and could likely be engineered using the
CRISPR tools developed for other Clostridium species.
Finally, CRISPR-Cas9 tools have also been developed for
Staphylococcus aureus [60–62], an opportunistic pathogen
commonly found on the skin [63]. Similarly to Clostridiae,
Staphylococci can either be beneficial commensals or patho-
gens depending on the genetic makeup of specific strains.
In addition to these microbiome-associated bacteria,
CRISPR-Cas9 tools have been developed for other bacterial
species including Bacillus subtilis [64]. In the future the catalo-
gue of bacteria that can be engineered with CRISPR tools will
likely continue to expand, enabling an increasing number of
applications.3. CRISPR editing of unicellular eukaryotes
While less studied than bacteria, commensal protozoans and
fungi are highly prevalent in healthy populations [65,66], and
some yeast can be used as probiotics in additive therapies.
Most famously Saccharomyces boulardii was isolated by the
French scientist Henri Boulard in 1923 with the purpose of
controlling the symptoms of diarrhoea and is now commonly
used as a probiotic. This yeast strain has been engineered
with CRISPR-Cas9 to introduce various modifications,
including the introduction of an exogenous metabolic path-
way and the production of human lysozyme [67].
Saccharomyces boulardii has also been engineered with the
help of CRISPR for the development of oral vaccines [68].
More generally, many CRISPR-Cas9 editing strategies have
been developed in Saccharomyces cerevisiae [69,70] as well as
microbiome-associated fungi, including the opportunistic
pathogen Candida albicans [71,72]. Along the same line,
CRISPR tools developed for protozoan parasites like Plasmo-
dium falciparum [73,74] could likely be adapted to commensal
protozoans like Blastocystis.4. CRISPR editing of bacteriophages
Phages have been applied to cure bacterial infections, with
many reported successes in various animal models of lung,
skin or gut infection. Engineered phages present interesting
subtractive therapeutic opportunities to treat infectious dis-
eases and target the microbiome. In particular, phage
adsorption elements like tail fibres and tail tips can be engin-
eered to modify their host range [75]. Temperate phages can
be engineered to remove potential virulence factors and
turned into lytic phages to limit the risks associated with
their use in phage therapy [76]. Phages can further be modi-
fied to disperse biofilm [77], encode antimicrobial proteins
[78] or other functions of interest. Temperate phages that
can be stably maintained in the bacterial cell as prophage
or plasmid can be engineered during their lysogenic cycle
using the tools described above. However, the modification
of lytic phages is particularly challenging as they never
reside as a stable genetic element in the cell and antibiotic
selection markers cannot be used.
Strategies to edit lytic bacteriophages with CRISPR tools
have now been developed. A guide RNA is designed to
target the phage genome and a genetic modification of inter-
est is typically cloned on a vector with homology arms to
promote recombination with the phage DNA. Shortly after
viral DNA entry, Cas nucleases cleave the target sequence
royalsocietypublishing.org/journal/rstb
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5and the lesion is repaired through recombination with the
provided template, resulting in the edited phage. Only
edited phages can then form plaques on bacteria carrying
the CRISPR-Cas9 system. This strategy was first demon-
strated using the type I-E CRISPR-Cas system of E. coli to
engineer phage T7 [79], followed shortly thereafter by a dem-
onstration that the CRISPR-Cas9 system from Streptococcus
thermophilus could be used to edit virulent phages of this bac-
terium [80]. These techniques have now been extended to
the engineering of Lactococcus lactis phage p2 [81], of phage
T4 in E. coli [82] and phage vB_BsuP-Goe1 in Bacillus subtilis
[83]. In one example, the type III CRISPR-Cas10 system from
Staphylococcus epidermidis has also been used to edit staphylo-
coccal phages [84]. Note that lytic phages can also be cloned
and engineered in yeast [75], where CRISPR-Cas9 tools are
readily available.
Beyond the possible use of natural or engineered bacterio-
phages to cure infections caused by specific pathogens, the
recent description of their role as key components of the
microbiome will likely open the way to new phage-based
therapies [85]. Not only can phages alter the structure of
the microbiome by infecting specific species, but they can
also alter the genotype and phenotype of the bacteria they
infect through horizontal gene transfer and lysogeny. As
such, phages likely contribute to the maintenance of the intes-
tinal homeostasis either in health or in disease (dysbiosis)
[86]. The use of temperate phages to influence the compo-
sition and phenotype of bacteria in the microbiome could
thus be viewed as an interesting modulatory therapeutic
strategy, but a better understanding of these complex ecologi-
cal interactions will be needed for the development of such
therapies.5. CRISPR antimicrobials
Besides their use to directly kill target bacteria, phages can be
used as DNA delivery vectors. Plasmids carrying a phage
packaging signal, known as phagemids, can be used to
deliver various effector DNA circuits to target bacterial popu-
lations. Phagemids can be packaged into phage particles in
the presence of a helper phage that carries all the elements
necessary for the production of functional capsids that are
missing from the phagemid DNA [87]. In addition, the
helper phage can be modified in order to block packaging
of its DNA [88]. The M13 phagemid was used to deliver var-
ious toxins or restriction enzymes to E. coli [89–91]. The Pf3
phage has also been used to a deliver a restriction enzyme,
and successfully treat a Pseudomonas infection in mice [78].
CRISPR-Cas systems themselves can be delivered to
populations of bacteria using this strategy with the purpose
of specifically eliminating bacteria carrying target sequences
in their genome. This strategy has already been demonstrated
in E. coli [92] and in S. aureus [93]. In the first study, a plasmid
carrying Cas9 and guide RNAs targeting antibiotic resistance
genes were injected into bacterial populations using the M13
phagemid system. Efficient cell death was observed as
expected when the target gene was present. In the second
study, a phagemid based on Staphylococcus phage phiNM1
was constructed by cloning its packaging site on a plasmid
carrying a CRISPR-Cas9 system. This phagemid was then
tested against various antibiotic resistance genes and viru-
lence factors. Both reports demonstrated the possibility ofusing CRISPR-Cas systems to eliminate a specific target bac-
terial genotype in a mixed population, both in vitro and
in vivo, testing a wax worm infection model in the former
case and a mouse skin colonization model in the second
one. These studies also investigated the outcome of targeting
a plasmid rather than the chromosome. Cas9 cleavage of a
target plasmid leads to cell survival and plasmid loss. Note
however that in cases where the plasmid carries a toxin–
antitoxin addiction system, the cells will die as a consequence
of plasmid loss.
In yet another study, it was proposed to use temperate
phages rather than phagemids in order to introduce CRISPR-
Cas systems in E. coli [94]. The CRISPR array was programmed
to cure plasmids carrying antibiotic resistance genes, thereby
sensitizing bacteria to antibiotics. In this work an additional
trick was played: a lytic phage was engineered to carry
sequences matching the guide RNAs encoded by the CRISPR
array. This phage could then be used to kill bacteria that
did not carry a functional CRISPR-Cas system and ensure the
fixation of the CRISPR prophage in the population.
CRISPR-based antimicrobials offer the possibility to
develop novel subtractive therapies, enabling the killing of
bacteria based on their sequence without disturbing the rest
of the microbiota. We now understand increasingly how
different strains of a given bacterial species can have pro-
foundly different effects on our health. The accessory
genome that differentiates bacterial strains includes genomic
islands, prophages and plasmids that impact the interaction
of bacteria with each other and with their host. These
elements frequently include virulence factors, toxins and anti-
biotic resistance genes [95,96]. CRISPR antimicrobials could
become a powerful tool both to study the effect of specific
strains by removing them from the microbiome, and to elim-
inate undesired strains as a therapeutic strategy. Note that
many bacteria carry active CRISPR-Cas systems of their
own that can also be harnessed to trigger self-targeting and
cell death. The different approaches to CRISPR antimicrobials
and the associated challenges have been reviewed in more
detail elsewhere [97,98].6. Controlling gene expression with CRISPR
Beyond the targeted elimination of strains and the genetic
modification of commensals, CRISPR-Cas systems can also
be engineered to modulate gene expression. These engineered
CRISPR-Cas systems could be used to modulate the activity
of bacteria used as probiotics in additive strategies, or
could directly be delivered to the resident bacteria of the
microbiome through transduction or conjugation (figure 2).
The Cas9 protein carries an HD nuclease domain and a
RuvC nuclease domain, each cleaving the target DNA on
a different strand [10]. Mutation of the catalytic residues
abolishes DNA restriction while maintaining strong on-
target binding. Binding of dCas9 to promoter sequences
strongly inhibits the initiation of transcription, while binding
inside transcribed regions can inhibit transcription elongation
[99,100]. Note that dCas9 is only able to efficiently block the
running RNA polymerase when it is guided by an RNA that
binds to the non-template (coding) strand of DNA. The level
of complementarity between the guide RNA and the target
can be used to control the rate at which RNA polymerase
‘kicks out’ dCas9 from the target and completes transcription
royalsocietypublishing.org/journal/rstb
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6[33]. This mechanism can be used to precisely and robustly
reduce gene expression by defined relative amounts, offering
a powerful tool to modulate the physiology of target bacteria.
Gene silencing with dCas9, also known as CRISPRi, is
comparatively much easier to perform than Cas9-mediated
genome editing in bacteria. This has led to the rapid and
broad adoption of this technology in a wide range of bacteria,
including pathogenic streptococci [100,101], Pseudomonas
[102], Staphyloccoci [103], Mycobacteria [104] and Mycoplasma
[105], as well as a large number of bacterial species of
industrial interest. Directly relevant to this review, dCas9
repression has also been performed in microbiome-associated
bacteria like Lactococcus lactis [106] and Bacteroides thetaiotao-
micron, where it was used to alter the bacterial metabolic
capacity and its resistance to antimicrobial peptides [107].
In the latter work, the CRISPRi repression was also shown
to be functional in the mouse gut.
It is also possible to repurpose dCas9 as a transcriptional
activator, in a strategy also known as CRISPRa. In a first
proof of concept, dCas9 was fused to the omega subunit of
the RNA polymerase, yielding moderate activation [100]. In
a recent study, activator domains were recruited to the
dCas9 ribonucleic complex using a more elaborate strategy.
Activator domains were fused to the MS2 coat protein,
which binds to a MS2 hairpin itself fused to the guide RNA
[108]. Several candidate activators could easily be tested in
this manner and strong activation was obtained with SoxS,
which could further be optimized to yield up to a 50-fold
increase in the expression of a target reporter gene. The
authors further showed how this design could be used to
activate silent metabolic pathways. Note however that this
strategy is very sensitive to the distance between the target
and the promoter. Binding needs to occur within a narrow
window roughly 60–90 bases upstream of the transcription
start site. When no PAM is available in the desired range, it
might not be possible to use this tool without further efforts
to modify PAM specificity [109].
One appealing feature of CRISPRi is how it can easily be
scaled to high-throughput genetic screens. Arrayed libraries
of guide RNAs have already proven very useful to investigate
the function of essential genes in B. subtilis and S. pneumoniae
[101,110]. Potential caveats of using dCas9 were discovered in
a recent study in which a pool of guide RNAs was used to
target approximately 105 positions in the chromosome of
E. coli [111]. This study revealed that dCas9 can cause off-
target effects at positions with as little as 9 nt of homology
to the guide RNA. The same study also revealed an unex-
pected toxicity of dCas9 in E. coli. Among other important
design rules, this work highlighted the importance of fine-
tuning the concentration of dCas9 to avoid this toxicity while
maintaining strong on-target repression. Using such an opti-
mized expression cassette and relying on the information
gathered by multiple guides targeting the same gene can
enable powerful screens to be performed using dCas9 [112,113].
Other types of CRISPR-Cas systems can also be used to
silence genes. In type I systems, the Cas3 nuclease is respon-
sible for DNA degradation. In its absence, the multiprotein
complex known as Cascade will bind target sequences with-
out introducing any DNA damage. This can be used to block
gene expression in the same manner as dCas9 [114,115]. The
dead variants of the Cas12 (Cpf1) protein from type V system
can also be used to block gene expression in bacteria, as
already demonstrated with Cas12 proteins of various origins[116–118]. Finally gene silencing can also be achieved at the
RNA level directly using the Cas13 protein from type VI
systems, which acts as a RNA-guided RNAse [12,119]. Note
however that Cas13 displays a non-specific RNAse activity
once it has found its target. This triggers collateral RNA
damage that is likely toxic to the cell and was seen to
reduce cell growth in E. coli [12]. This collateral activity
makes it impractical to silence genes in bacteria, but variants
of Cas13 might be identified in the future that only carry a
specific RNAse activity. Technologies have also been devel-
oped to edit RNA with a deactivated Cas13 fused to a base
modification domain [120].
CRISPRi and CRISPRa have also been adapted to
eukaryotic cells and—of particular relevance to this review—
to Saccharomyces cerevisiae [121], where it could help in the devel-
opment of probiotic yeast. Note that while dCas9 itself can
efficiently block transcription in bacteria, CRISPRi in eukaryotic
cells requires the fusion of dCas9 to effector domains.7. Challenges and future prospects
Over the past few years, we have seen the application of
CRISPR tools to organisms as diverse as Firmicutes, Proteo-
bacteria, yeasts and human cells. The fact that the Cas9
protein from S. pyogenes worked easily in so many different
cellular backgrounds was surprising to many. This bodes
well for the future applications of CRISPR technologies to
the extremely diverse set of organisms that compose our
microbiome, even though Cas9 from different origins, or
even other Cas proteins, might be better suited than others
to specific organisms.
While CRISPR-Cas systems seem easily portable between
species, one key consideration is that the outcome of DNA clea-
vage by Cas nucleases can be very different depending on the
type and efficiency of the DNA repair pathways present in
different organisms. As an example, Cas9 cleavage in the
chromosome of mammalian or yeast cells leads to DNA
repair through homologous recombination or non-homologous
end joining, while the main outcome of efficient Cas9 cleavage
in bacterial genomes is cell death. This is likely owing to the
absence or poor efficiency of non-homologous end joining
(NHEJ) systems in most bacterial species. Among bacteria
that naturally carry NHEJ systems, Cas9 breaks could be
repaired by NHEJ in some species but not others
[55,122,123]. Efforts to import NHEJ systems into bacteria
that lack them have yielded limited success [20,123,124].
Different bacterial species also carry more or less efficient
homologous recombination systems. Bacteria that can undergo
natural transformation and efficient homologous recombination
can easily be modified using CRISPR-Cas9 tools, while other
bacteria like E. coli require the use of an exogenous recombina-
tion system [26]. This heterogeneity in DNA repair capabilities
between organisms means that specific tools and strategies
need to be designed for different species. CRISPR tools
that do not rely on DNA cleavage will likely be more easily
portable. These include base editing and CRISPRi strategies.
One of the main obstacles for the broad adoption of these
technologies to manipulate members of the microbiome is the
difficulty of introducing exogenous DNA in many bacterial
species. Some bacteria are more or less amenable to tech-
niques such as electroporation, conjugation or transduction.
Many bacteria also carry restriction systems that destroy
royalsocietypublishing.org/journal/rstb
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7incoming DNA. Others might not be able to replicate plasmid
DNA if the origin of replication is not carefully chosen.
Finally, bacteria that cannot be easily grown in the laboratory
are obviously hard to engineer. These obstacles are not
specific to CRISPR technologies and researchers have found
ways to engineer many bacterial species through the con-
struction of dedicated vectors. CRISPR tools thus need to
be redesigned to fit the requirements of individual target
species. Finding more standardized approaches and more
universal tools to deliver DNA to bacteria would go a long
way to accelerate research and engineering of a diverse set
of bacteria. In a recent study, Peters and colleagues used con-
jugation and transposition for DNA delivery and integration
in the bacterial chromosome to facilitate the use of CRISPRi in
many species [125]. Beyond the use of CRISPR tools in vitro,
conjugation as well as phage delivery systems enable the
delivery of DNA directly in vivo and could be used for
the development of novel therapies. Both transduction
and conjugation also open the possibility of targetting non-
culturable bacteria directly in their natural environment.
Phage particles can be used to deliver DNA efficiently into
specific bacterial strains, however this specificity is such
that dedicated phage capsids will likely have to be engin-
eered for each therapeutic indication. The host range of
bacteriophage capsids can be extended through the modifi-
cation of the proteins that interact with the bacterial
envelope such as the tail fibres [75]. In a recent study,
Qimron and colleagues employed a directed evolution
approach to extend the host range of bacteriophage particlesfor DNA transduction [126]. This type of approach will be
critical to engineer delivery vectors for a wide range of
target bacteria, but whether transduction or conjugation
can efficiently reach the right bacteria in the complex
spatial structure of the microbiome largely remains to
be investigated.
The increasing knowledge of the profound impact that
the microbiome has on human health is driving the develop-
ment of novel therapeutic avenues to treat infectious disease,
metabolic disease, immune disease and even neurological
disorders. However, the outcome of current therapies that
target the microbiome is often uncertain owing to our limited
understanding of the complex ecological interactions that
occur within microbial communities and with the host
immune system. CRISPR tools provide exciting strategies
not only to study the biology of microbes, but also to eluci-
date their role within complex communities and drive the
development of novel therapies.
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